Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Carcinoma, Lobular 1Brain Neoplasms 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × repotrectinib × 1 year × Clear all
NCT06552234 2026-04-13

REPOROS

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Phase 2 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06315010 2026-02-25

REPOSE

MedSIR

Phase 2 Recruiting
20 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡